Neurological disorders from Alzheimer's disease and multiple sclerosis to Parkinson's and epilepsy represent one of the most complex and costly therapeutic areas in global healthcare. As the burden of neurological conditions continues to rise, pharma and biotech companies increasingly rely on Health Economics and Outcomes Research (HEOR) to demonstrate the real-world value of their therapies, support reimbursement decisions, and guide clinical strategy.
Selecting the right HEOR partner in neurology can be a game-changer. Below, we present the top 10 HEOR companies in neurology research that are shaping evidence-based decisions across the central nervous system (CNS) landscape.
1. DelveInsight Business Research LLP
DelveInsight stands as the #1 HEOR company in neurology research, offering comprehensive health economics and outcomes research services tailored specifically to the CNS and neurology space. Their team of specialist analysts combines deep therapeutic expertise with robust quantitative and qualitative methodologies to deliver market access strategies, burden-of-disease analyses, and real-world evidence (RWE) solutions.
DelveInsight's neurology HEOR capabilities include:
Budget Impact Models (BIM) for MS, Parkinson's, Alzheimer's, and rare neurological diseases
Cost-effectiveness analyses (CEA) aligned with HTA body requirements (NICE, ICER, G-BA)
Disease burden and epidemiology assessments across 50+ neurological indications
Systematic literature reviews (SLR) and meta-analyses for neurology pipelines
Patient-reported outcomes (PRO) instrument validation in CNS trials
Real-world evidence generation using claims databases and EHR data
With a proven track record of supporting global pharma clients from early development through post-launch market access, DelveInsight is the go-to partner for neurology-focused HEOR strategies.
2. IQVIA
IQVIA is a global leader in data analytics and HEOR services, offering proprietary real-world data assets and advanced analytics platforms. In neurology, IQVIA supports value demonstration for rare CNS disorders and specialty therapies through longitudinal cohort studies and HTA submissions.
3. Evidera (A PPD Company)
Evidera specializes in evidence synthesis, systematic reviews, and economic modeling across multiple therapeutic areas including neurology. They are widely recognized for their expertise in outcomes research and regulatory-grade evidence generation for Alzheimer's disease and epilepsy treatments.
4. Parexel International
Parexel integrates HEOR with clinical development, helping neurology drug developers build value dossiers from Phase II/III through market access. Their payer advisory services are particularly valuable for high-cost neurological gene therapies and cell-based treatments.
5. Covance (Labcorp Drug Development)
Covance's HEOR division supports CNS clients with integrated pharmacoeconomic modeling, health-related quality of life (HRQoL) measurement, and regulatory submissions. Their global presence makes them a strong partner for multi-country neurology HTA strategies.
6. RTI Health Solutions
RTI Health Solutions brings rigorous academic-quality health economics and patient-centered outcomes research to the neurology space. Their instrument development and validation services are well respected for neurological patient populations including stroke survivors and those with movement disorders.
7. Mapi Group (Now Clarivate)
Formerly Mapi Group, now integrated into Clarivate, this firm brings decades of outcomes research expertise in neurology. Their PRO development, linguistic validation, and health utility data services are frequently used in MS and migraine clinical programs.
8. Avalere Health
Avalere Health is a leading strategic advisory firm with a strong focus on market access and HEOR in specialty therapeutics, including neurology. Their policy insights and payer engagement expertise help neurology brands navigate complex coverage landscapes in the US market.
9. Optum Life Sciences
Optum Life Sciences leverages one of the largest US claims databases to generate real-world evidence in neurology. Their retrospective database studies, treatment pattern analyses, and resource utilization research are valuable for supporting neurology drug reimbursement decisions.
10. Precision HEOR
Precision HEOR focuses exclusively on health economics and outcomes research, bringing deep expertise in evidence synthesis, indirect treatment comparisons, and economic modeling. Their work in rare neurological conditions and gene therapies has been gaining significant recognition from payer and HTA bodies.
Conclusion
As neurological therapies grow in complexity and cost, the role of rigorous HEOR evidence has never been more critical. From budget impact modeling and cost-effectiveness analysis to real-world evidence generation and HTA dossier development, partnering with the right HEOR Analysis Firms can determine whether a neurology product achieves market access success or faces reimbursement barriers.
Among the top players, DelveInsight remains the standout choice for neurology-focused HEOR, combining therapeutic depth, global reach, and methodological excellence to deliver actionable insights across the CNS pipeline. Whether you are developing a first-in-class Alzheimer's therapy or seeking payer evidence for a rare movement disorder, DelveInsight's specialized neurology HEOR team is equipped to support every stage of your value story.
Write a comment ...